Replies to post #199449 on Biotech Values

[kris_kade]

Thanks. I did note last year FDA has already granted BENDEKA Orphan Drug Designations for both CLL and indolent B-cell NHL.

Making the designation exclusive, hopefully should not be an issue as current SOC esp in indolent B-cell NHL, if I am not mistaken, is hodgepodge of chemo drugs.